Parkinson's Disease/Movement Disorders News

An automated machine-learning method that analyzed sleep movements recorded with a conventional 2D camera may improve diagnosis of rapid eye movement sleep behavior disorder, according to a study published in Annals of Neurology.

Treatment with an oral allosteric modulator was nonsuperior to placebo at 6 weeks in adults with Parkinson’s disease whose symptoms included fall risk and cognitive issues, data from JAMA Neurology show.

The average wait time between a referral and neurologist visit was more than a month among older adults, with longer wait times for those with serious neurodegenerative conditions like MS, epilepsy and Parkinson’s disease, new research shows.

Healio Neurology looks back at the most-viewed stories during the past year. Highlights include Biogen’s discontinuation of Aduhelm and a former NIH neuroscience director found guilty of research misconduct.

The Parkinson's Foundation has issued new recommendations to improve the standard of care for hospitalization among individuals with Parkinson’s disease.

A Phoenix-area medical technology company has received $4.2M grant fromThe Michael J. Fox Foundation for Parkinson’s Research to support a study for a skin test that quantifies abnormal alpha-synuclein in those with Parkinson’s disease.

Many individuals diagnosed with anti-NMDA receptor encephalitis continued to have cognitive issues — particularly with memory and language — up to 3 years after diagnosis, according to a recent study.

ADx NeuroSciences and Alamar Biosciences have announced a partnership to develop customized biomarker assays for companies that advance novel therapeutics for a range of neurological conditions.

Topline data from a phase 2 clinical trial of an investigational gene therapy for Parkinson’s disease showed that a higher dose of the medication significantly improved disease-specific and quality of life measures by week 26.